Skip to content
Bending the Curve Trial by Trial
?

Phase III Trial of Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Paclitaxel With or Without Trastuzumab as Adjuvant Treatment for Women With HER-2 Over-Expressing or Amplified Node Positive or High-Risk Node Negative Breast Cancer

Phase 3NCT00005970

Population
Women with surgically removed HER2-positive breast cancer
Design
Randomised three-regimen trial; the joint analysis with NSABP B-31 compared group A with group C (concurrent trastuzumab); group B (trastuzumab after paclitaxel) was excluded from the joint analysis. See trial b31-n9831-joint.
Arms
  • Group A (control): Doxorubicin and cyclophosphamide followed by weekly paclitaxel
  • Group B (experimental): The same regimen followed by 52 weeks of trastuzumab after paclitaxel
  • Group C (experimental): The same regimen plus 52 weeks of trastuzumab initiated concomitantly with paclitaxel
People
Romond EH
Primary publication: Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353(16):1673-84. PubMedDOI

Appears in

Sources

  1. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353(16):1673-84.

    PubMedDOI